Summary Telomerase, a ribonucleoprotein enzyme, has been found in immortalized but not in most somatic adult human tissues, and thus emerged as a novel target for cancer chemotherapy. However, its usefulness could still be limited by normal tissue toxicity. This study compares enzyme activity in tissues and tumours in conventional in vivo models and human biopsy material, specifically normal human liver, with a view to determining the therapeutic potential of anti-telomerase therapy. The telomeric repeat amplification protocol (TRAP assay) was used to measure enzyme activity and levels were semiquantified by assaying equal concentrations of cellular protein. Telomerase activity was high in the murine embryonic stem cell line CGR8.8, WRL 68 human embryo liver cells, testis, ovary and liver of adult mouse and rat. Low activity was detected in normal human liver, marmoset and pig liver. Very low enzyme activity was seen in mouse, rat and marmoset bone marrow, brain or skin; no activity could be detected in mammalian lung and heart. On the contrary, all 30 human and murine malignant tissues studied showed high to moderate enzyme levels. However, activity found in murine liver was often higher than in tumour, e.g. in the transplantable adenocarcinoma of the colon MAC16. Our findings indicate that telomerase is present not only in murine but also in other normal mammalian tissues such as liver, and that this activity might result from the presence of somatic stem cells. In view of this, the role of telomerase as a potential selective target for therapy needs further investigation. Furthermore, the understanding of regulatory pathways of this enzyme and the selection of screening models will be critical.
Telomeres are protein-DNA structures at the chromosomal ends of eukaryotic cells that allow a cell to distinguish intact from broken chromosomes, protect from end degradation or recombination and are substrates for novel replication mechanisms (Zakian, 1995; Rhyu, 1995) . Telomeres are usually replicated by telomerase, a telomere-specific reverse transcriptase that adds telomeric repeats onto chromosomal ends using a segment of its RNA component (hTR) as a template (Feng et al, 1995) . The vertebrate tandem repeat sequence is TTAGGG. Progressive telomere shortening has previously been linked to cell senescence and ageing (Harley et al, 1990) . A current hypothesis proposes that activation of the nucleoprotein enzyme telomerase is essential for cells to overcome cellular senescence, and thus indefinite proliferation/immortality and malignant progression are associated with telomerase activity (Kim et al, 1994; Chadeneau et al, 1995a; Bednarek et al, 1995) . In agreement with this idea, telomerase activity has been detected in almost all human cancers, including ovary, breast, prostate, colon, stomach, liver, brain, neuroblastomas, etc. (Kim et al, 1994; Rhyu et al, 1995) . So far, in all the tumour tissues examined, 85% have telomerase activity, but activity has been seen in only 4% of normal/adjacent specimens. Among the normal adult human tissues examined, telomerase activity was reported in germline cells and little activity was seen in normal bone marrow and peripheral blood leucocytes and lymphoid cells or epidermis of skin (Broccoli et al, 1995; Hiyama et al, 1995; Taylor et al, 1996; Wright et al. 1996) . The function and presence of telomerase activity in these renewable tissues however remains largely undefined. Telomerase has therefore emerged as an attractive potential target for cancer chemotherapy (Chadeneau et al, 1995b; Morin, 1995; Parkinson, 1996) .
To enable testing of anti-telomerase strategies, appropriate in vivo models need to be available to assess potential candidate drugs for activity and to predict toxicological indices. As it seems likely that pure/specific telomerase inhibitors will need prolonged use, and efficacy could only be judged by monitoring telomere length as an end point (Parkinson, 1996) , the identification of adequate tumour and in vivo systems will be critical. Chadeneau et al (1995b) have previously studied a transgenic mouse model overexpressing the neu gene. In this study, we investigated the feasibility of conventional murine transplantable tumours to assess potential telomerase inhibitors by comparing telomerase activity in tumour vs normal tissues. We further examined telomerase expression in organs of a variety of mammalian species that are critical to drug toxicity, especially liver, an organ with regenerative capacity (Vandersteenhoven and Burchette, 1990; Gibson-D'Ambroso et al, 1993) .
MATERIALS AND METHODS Tissues Surgical specimens were flash frozen in liquid nitrogen immediately after removal and stored at -80°C. For telomerase extraction approximately 30 mg of tissue was washed twice in ice-cold phosphate-buffered saline (PBS), then in telomerase washing buffer [(10 mm Hepes-potassium hydroxide pH 7.5, 1.5 mm magnesium chloride, 10 mm potassium chloride, 1 mm DYT (Kim et al, 1994) ] and finally homogenized in about 250 pl of lysis buffer [10 mm TrisHCl pH 7.5, 1 mm magnesium chloride, 1 mm EGTA, 0.1 mM phenylmethylsulphonylfluoride (PMSF) 5 mm 2-ME, 0.5% CHAPS, 10% glycerol (Kim et al, 1994) ] using a sterile glass tissue homogenizer (Merck, Lutterworth, UK). Homogenates were kept on ice for 30 min and were then centrifuged at 25 000 g for 30 min at 4'C (Beckman, Optima TL Ultracentrifuge). Supernatant was carefully removed and stored at -80°C. Total cellular protein was determined by Bradford assay (Bradford, 1976 NADPH-cytochrome c (P450) reductase activity was measured as a functional liver control enzyme (Gibson and Skett, 1986) .
Animal tissues
Certified pathogen-free mice and rats were supplied by B&K, Hull, UK. Marmoset tissues were derived from an in-house colony. The MAC transplantable adenocarcinomas of the colon were derived from routinely passaged tumour fragments and are described elsewhere (Double et al, 1975) . All animal experiments were conducted in compliance with a UK Home Office Licence.
Cell lines
The human skin fibroblast cell lines used, WRL 68 human embryonic liver cells and the WEHI 3B mouse leukaemia line were obtained from the European Collection of Animal Cell Cultures (Porton Down, UK). The human breast fibroblast line BTS30 and the MAC colon carcinoma cell lines were established as reported previously (Phillips et al, 1990; Hambly, 1994 Tumour cells were routinely passaged and cultured in RPMI-1640 medium supplemented with 10% fetal calf serum and 2 mm L-glutamine. Fibroblast cell lines were maintained in Eagle's minimum essential medium containing 2 mM L-glutamine, 15% fetal calf serum and 1% non-essential amino acids. For extraction of telomerase activity, exponentially growing cells were trypsinized, pelleted, the pellet washed and lysed as described previously (Kim et al, 1994) and the amount of total cellular protein determined using the Bradford method.
Protein assay
The Bio-Rad protein assay (Bio-Rad Laboratories, Munich, Germany), based on the Bradford methodology, was used to determine protein content in cell and tissue extracts according to the Telomerase activity
The conventional TRAP assay, as described by Kim et al. (1994) , was followed with minor modifications.
Multiple concentrations ranging from 6.0 to 0.006 jg of total cellular protein for tissue and from 10 to 0.001 jg of protein for cell lines were assayed to determine the optimum protein concentration for the polymerase chain reaction (PCR) based measurement of telomerase activity. Tenfold dilutions were freshly prepared in sterile diethyl polycarbonated water just before addition to the TRAP reaction. Optimal protein concentrations for cell lines, which just saturate the PCR reaction but do not inhibit the Taq-DNA polymerase were found to be 1.0-0.1 jg for pure cell populations and 0.60.06 jig for tissues.
TRAP assay
The TS primer was used for the telomerase extension reaction, a non-telomeric synthetic oligonucleotide with the sequence 5'-AATCCGTCGAGCAGAGTT-3', and the CX primer, 5'-CCCT-TACCCTTACCCTTACCCTAA-3', was used as PCR primer and is initially separated from the rest of the reaction mix by a wax barrier (Ampliwax, Perkin Elmer, Branchburg, NJ, USA). To enable autoradiographic detection 2.0 gCi of [ac-32P] 
RESULTS
An absolute quantitative analysis of telomerase activity is complicated by the limitations inherent in the PCR-based TRAP assay technique. In an attempt to give a general overview of the data described in detail below, telomerase activity of various mammalian tissues was rated relatively (visually ranked) to enzyme activity of a high-expressing tumour control cell line and is summarized in Table 1 .
In agreement with previous publications on telomerase activity in certain experimental mouse strains (Blasco et al, 1995;  British Journal of Cancer (1997) (Figure 3 ) and all other human tumour-derived cell lines and tissues examined in this study, did express marked Figure 2 , Sem., represents a seminoma specimen; Figure 4 Susa CP is a testicular cancer cell line). In view of the possibility that normal human cells and tissues might also be sensitive to potential telomerase inhibitors, we focused here on determination of telomerase activity in healthy human liver. Human testicular tissue and peripheral blood lymphocytes (PBLs) were also assayed. Telomerase activity was prominent in male germ-cell tissue, and very low in a pool of three healthy adult PBL samples (Figures 2 and 5) . In marked contrast to the current opinion (Kim et al, 1994; Chadeneau et al, 1995a; Piatyszek et al, 1995; Prowse et al, 1995; Tahara et al, 1995) , we were also able to detect weak telomerase activity in human liver derived from seven healthy transplant livers and three normal liver samples from cancer patients (Figures 4 and 5) . These rather unexpected observations prompted us to assay liver tissue from other higher mammalian species such as rat, pig (data not shown) and monkey. These also expressed telomerase activity (Figure 4 ). It appears that the intensity of the telomerase signal decreases from mouse to rat and monkey and in the pig to human in relation to organ size.
In an attempt to explain the observed telomerase activity in normal primate liver, we assumed that telomerase activity results British Journal of Cancer (1997) 75(4) . (Figure 5 ). The hexanucleotide ladder pattern observed in the mammalian liver samples was RNAase sensitive (in Figures 1 and 4 shown for rat and mouse) and in case of WRL 68 also inhibitable in cultured cells with cisplatin, a proposed telomerase inhibitor (Burger et al, 1996) (Figure 5 ).
To determine whether quality and quantity of the rarely avail- reported weak telomerase activity in apparently non-cancerous liver tissues of patients with cirrhosis and hepatitis (Tahara et al, 1995) , two conditions in which human liver has been shown to be proliferative and express 'ductular hepatocytes' and/or facultative stem cells (Vandersteenhoven and Burchette, 1990) . It is noteworthy that the latter study used the Bradford method to determine cellular protein and that other authors (Chadeneau et al, 1995a) cautioned that quality of biopsy material might contribute to negative results of histologically normal liver samples. and skin epidermis (Taylor et al, 1996) confirms the stem cell theory. The presence of somatic stem cells expressing telomerase activity in normal human liver is further supported by the data of Gibson-D'Ambrosio et al (1993) , who found that long-term culturing of functionally active, normal human adult liver hepatocytes (containing precursor stem cells) was possible, but not that of terminally differentiated hepatocytes. Concordantly, other investigators proposed that the ease of successfully establishing primary tissue cultures from mouse tissues in general and in particular from mouse and rat hepatocytes could be explained by the considerably high telomerase levels in livers of these animals (Prowse et al, 1995) . Although earlier studies had demonstrated that the human telomerase RNA component is expressed in many adult organs including liver, the authors were not able to detect telomerase activity (Avilion et al, 1995; Feng et al, 1995) . Conclusive explanations for the phenomenon were not given. Although this could be due to suppression/negative regulation of telomerase protein in the tissues concerned, technical limitations inherent in the assay as discussed above cannot be ruled out.
The latter seems to be more likely as Holt et al (1996) recently reviewed and refined the 'telomere-telomerase hypothesis of aging and cancer' and postulated that low telomerase activity might be found in many normal tissues. This was attributed to activated telomerase competent cells (stem cells) in regenerative tissues with high proliferative need, in which telomere loss would possibly prevent replenishment. The same authors propose the presence of three different cell types, germ cells with high telomerase activity and telomeres maintained, stem cells with medium activity and in which telomeres shorten, and finally normal cells with no activity and significant telomere loss. However, they believe that such normal stem cells remain quiescent most of their life span and might therefore not be significantly effected by antitelomerase therapy.
Viewed from another perspective, the presence of telomerase activity in cells that are not terminally differentiated, including renewal tissue stem cells etc., might be vital for these cells and impact the wider cellular regulatory pathway. Therefore treatment with inhibitors could result in severe organ toxicity. As mouse in particular, but also rat and even monkey or pig, seem to have telomerase activity in critical organs with only marginal differences to levels in tumour tissues, it will be difficult to evaluate the therapeutic potential of novel antagonists in these animals.
With the proposed function of telomerase, even complete enzyme inhibition would not produce acute cell death; cell senescence and subsequent cell death would result from progressive telomere shortening during successive cell divisions. This greatly complicates the assessment of inhibitors as potential anticancer agents as tumours will continue to grow in size following complete and even selective inhibition of telomerase activity. Thus a 'perfect' inhibitor may appear inactive in many of the currently used experimental animal model systems. Moreover, during the telomere shortening process tumour burden could limit the animal life span or, considering that the difference in telomerase expression between certain tumours and normal tissues is marginal only, the therapeutic index for anti-telomerases could prove too small to demonstrate anti-tumour activity in a tolerated dose-response relationship. Therefore combination chemotherapy with standard cytotoxic agents and novel approaches in the development of tumour models need careful consideration if telomerase is to be a target for cancer chemotherapy.
